文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

组织灌注导向复苏在休克中的效果:一项系统评价与Meta分析

The effectiveness of tissue-perfusion-guided resuscitation in shock: A systematic review and meta-analysis.
PubMed 文献 · Ann Intensive Care · 2026-06-25
一句话结论组织灌注导向复苏未显著降低休克患者30天或90天死亡率,但可减少早期6-8小时输液量(MD -466.95 mL)并可能缩短ICU住院时间。

该系统评价与Meta分析遵循PRISMA 2020指南,检索MEDLINE、Embase和CENTRAL(2025年10月26日),纳入8项随机对照试验、共2,394例成人休克患者,比较组织灌注导向治疗(TP-GT)与标准治疗。TP-GT未显著降低30天死亡率(RR 0.96;95%CI 0.83-1.10;P=0.49)或90天死亡率(RR 0.94;95%CI 0.82-1.07;P=0.17)。TP-GT组ICU住院时间较短(MD -0.72天;95%CI -1.42至-0.01;P=0.048),但敏感性分析显示该结果不稳健;TP-GT显著减少复苏最初6-8小时的输液量(MD -466.95 mL;95%CI -917.17至-16.72;P=0.046)。作者认为TP-GT通过显著减少早期输液促进个体化液体管理,并可能与更短的ICU住院时间相关。

要点

  • 8项RCT、2,394例成人休克患者:TP-GT与标准治疗相比,30天死亡率无显著差异(RR 0.96;95%CI 0.83-1.10;P=0.49)。
  • 90天死亡率同样无显著差异(RR 0.94;95%CI 0.82-1.07;P=0.17)。
  • TP-GT组ICU住院时间较短(MD -0.72天;95%CI -1.42至-0.01;P=0.048),但敏感性分析显示该结果不稳健。
  • TP-GT显著减少复苏最初6-8小时输液量(MD -466.95 mL;95%CI -917.17至-16.72;P=0.046)。
  • 作者认为TP-GT通过显著减少早期输液促进个体化液体管理,并可能与更短的ICU住院时间相关。

适用人群与场景

  • 成人休克患者(纳入8项比较TP-GT与标准治疗的随机对照试验,共2,394例)。

研究设计与关键结果

  • 研究类型:系统评价与Meta分析,遵循PRISMA 2020指南,方案在PROSPERO前瞻性注册(CRD420251163043),检索MEDLINE、Embase和CENTRAL(2025年10月26日),纳入比较TP-GT与标准治疗的随机对照试验,采用随机效应模型,RoB2工具评估偏倚风险。
  • 共纳入8项RCT、2,394例成人休克患者。
  • 主要终点:TP-GT未显著降低30天死亡率(RR 0.96;95%CI 0.83-1.10;P=0.49),也未显著降低90天死亡率(RR 0.94;95%CI 0.82-1.07;P=0.17)。
  • 次要终点:TP-GT组ICU住院时间较短(MD -0.72天;95%CI -1.42至-0.01;P=0.048),但敏感性分析显示该结果不稳健。
  • 次要终点:TP-GT显著减少复苏最初6-8小时输液量(MD -466.95 mL;95%CI -917.17至-16.72;P=0.046)。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析(8项随机对照试验,2,394例患者)。
  • 偏倚风险评估工具:RoB2。
  • 局限:ICU住院时间缩短的发现经敏感性分析显示不稳健。

对床旁实践的改变

  • 作者认为TP-GT通过显著减少早期输液促进个体化液体管理,并可能与更短的ICU住院时间相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Resuscitation from shock generally targets macrohemodynamic parameters. However, this approach may not be followed by improved microcirculation and carries a risk of fluid overload. We aimed to evaluate the efficacy of tissue-perfusion-guided therapy (TP-GT) compared with standard care in adult patients with shock. Following the PRISMA 2020 guidelines, we searched MEDLINE, Embase, and CENTRAL on October 26, 2025, for randomized controlled trials (RCTs) comparing TP-GT to standard therapy. The protocol was prospectively registered on PROSPERO (CRD420251163043). The primary outcomes were 30-day and 90-day mortality. Secondary outcomes included intensive care unit length of stay (ICU LOS), hospital length of stay (HLOS), fluid administration volumes, fluid balances and organ support requirements. The meta-analyses were performed using the random-effect model, and the risk of bias was assessed using the RoB2 tool. Eight RCTs were analyzed, comprising 2,394 patients. TP-GT did not significantly reduce either 30-day mortality (Risk Ratio [RR] 0.96; 95% CI 0.83-1.10; P = 0.49) or 90-day mortality (RR 0.94; 95% CI 0.82-1.07; P = 0.17) compared to standard care. However, patients managed with TP-GT were associated with a shorter ICU LOS (Mean Difference [MD] -0.72 day; 95% CI -1.42 to -0.01; P = 0.048), although this finding proved fragile in sensitivity analyses. Furthermore, TP-GT significantly reduced the volume of fluid administered through the first 6-8 h of resuscitation (MD -466.95 mL; 95% CI -917.17 to -16.72; P = 0.046). It promotes personalized fluid stewardship by significantly reducing early fluid administration and may be associated with shorter ICU LOS.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Tóth T, Schneidereit P, Hollosi J, et al. The effectiveness of tissue-perfusion-guided resuscitation in shock: A systematic review and meta-analysis. Ann Intensive Care. 2026. PMID: 42434600. doi:10.1016/j.aicoj.2026.100106

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。